Press releaseBusiness Wire
Amylyx Pharmaceuticals
AMLX · NASDAQ
$28.77+$1.44 (+5.27%)TodayMarket closed ·
Prev close $27.33
Latest news
- News
Amylyx Pharma Q2 2026 Earnings Call Transcript
- Press releaseBusiness Wire
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
- Press releaseBusiness Wire
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
- Press releaseBusiness Wire
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
- News
Benzinga Bulls and Bears: Ross, Moderna, Webull
- Press releaseBusiness Wire
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
- NewsShivdeep Dhaliwal
Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' Radars Today
- Press releaseBusiness Wire
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Gains 1%; US Pending Home Sales Fall In July
- NewsVandana Singh
Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
Market-Moving News for August 18th
- Press releaseBusiness Wire
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- NewsAdam Eckert
Amylyx Pharmaceuticals Stock Soars After the Close: Here's Why
- Press releaseBusiness Wire
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
- Press releaseBusiness Wire
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
- Press releaseBusiness Wire
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
- Press releasePRNewswire
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- Press releaseBusiness Wire
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
- Press releaseBusiness Wire
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
- Press releaseBusiness Wire
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseBusiness Wire
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
- Press releaseBusiness Wire
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
- Press releaseBusiness Wire
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
- Press releasePRNewswire
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- Press releaseBusiness Wire
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
- Press releaseBusiness Wire
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.